Serological findings following the second and third SARS‐CoV‐2 vaccines in lung transplant recipients

INTRODUCTION: Lung transplant recipients (LuTX) represent a vulnerable population for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Even though many vaccines are already developed, more clinical data need to support effective immunological response in immunocompromised patients. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Bárczi, Enikő, Varga, Viktória, Nagy, Alexandra, Eszes, Noémi, Jáky‐Kováts, Zsuzsanna, Müller, Veronika, Bohács, Anikó
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311263/
https://www.ncbi.nlm.nih.gov/pubmed/35894705
http://dx.doi.org/10.1002/iid3.646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311263/
https://www.ncbi.nlm.nih.gov/pubmed/35894705
http://dx.doi.org/10.1002/iid3.646

Ejemplares similares